ES2076160T3 - Analogos de las subunidades de la toxina de bordetella obtenidos a partir de adn recombinante. - Google Patents
Analogos de las subunidades de la toxina de bordetella obtenidos a partir de adn recombinante.Info
- Publication number
- ES2076160T3 ES2076160T3 ES88308124T ES88308124T ES2076160T3 ES 2076160 T3 ES2076160 T3 ES 2076160T3 ES 88308124 T ES88308124 T ES 88308124T ES 88308124 T ES88308124 T ES 88308124T ES 2076160 T3 ES2076160 T3 ES 2076160T3
- Authority
- ES
- Spain
- Prior art keywords
- recombinant dna
- subunits
- toxin subunit
- bordetella
- analogs obtained
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000588807 Bordetella Species 0.000 title abstract 2
- 239000003053 toxin Substances 0.000 title abstract 2
- 231100000765 toxin Toxicity 0.000 title abstract 2
- 108020004511 Recombinant DNA Proteins 0.000 title 1
- 230000002163 immunogen Effects 0.000 abstract 2
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 abstract 1
- 238000012270 DNA recombination Methods 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 231100000776 exotoxin Toxicity 0.000 abstract 1
- 239000002095 exotoxin Substances 0.000 abstract 1
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
EL DESARROLLO DE SUBUNIDADES Y ANALOGOS DE SUBUNIDADES DE LA EXOTOXINA DE BORDETELLA POR MEDIO DE TECNICAS DE RECOMBINACION DE DNA PROPORCIONA PRODUCTOS ADECUADOS PARA LA FABRICACION DE VACUNAS QUE RETIENEN SU ACTIVIDAD BIOLOGICA, SON ALTAMENTE INMUNOGENICOS Y PUEDEN PROPORCIONAR PROTECCION ANTE EL RIESGO DE ENFERMEDAD. MODIFICACIONES EN LAS SUBUNIDADES PRODUCIDAS A TRAVES DE INGENIERIA GENETICA PUEDEN DAR COMO RESULTADO PRODUCTOS QUE RETIENEN SU CAPACIDAD INMUNOGENICA, PERO QUE CARECEN DE LA ACTIVIDAD ENZIMATICA ASOCIADA CON LA TOXINA.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9430787A | 1987-09-04 | 1987-09-04 | |
US94307 | 1987-09-04 | ||
US23248288A | 1988-08-17 | 1988-08-17 | |
US232482 | 1988-08-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2076160T3 true ES2076160T3 (es) | 1995-11-01 |
ES2076160T5 ES2076160T5 (es) | 2004-12-01 |
Family
ID=26788722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES88308124T Expired - Lifetime ES2076160T5 (es) | 1987-09-04 | 1988-09-01 | Analogos de las subunidades de la toxina de bordetella obtenidos a partir de adn recombinante. |
Country Status (16)
Country | Link |
---|---|
US (1) | US5773600A (es) |
EP (2) | EP0306318B2 (es) |
JP (1) | JP2918895B2 (es) |
KR (1) | KR0168039B1 (es) |
CN (1) | CN1033866C (es) |
AT (1) | ATE125568T1 (es) |
CA (1) | CA1341560C (es) |
DE (1) | DE3854213T3 (es) |
DK (1) | DK175821B1 (es) |
ES (1) | ES2076160T5 (es) |
FI (1) | FI101632B1 (es) |
GR (1) | GR3017497T3 (es) |
IE (1) | IE69753B1 (es) |
IL (3) | IL87608A0 (es) |
NO (2) | NO301844B1 (es) |
WO (1) | WO1989001976A1 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5925546A (en) * | 1987-11-02 | 1999-07-20 | Chiron S.P.A. | Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine |
US6713072B1 (en) * | 1987-11-02 | 2004-03-30 | Chiron S.R.L. | Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine |
IT1223334B (it) * | 1987-11-02 | 1990-09-19 | Sclavo Spa | Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse |
US5332583A (en) * | 1987-11-24 | 1994-07-26 | Connaught Laboratories Limited | Vaccine containing genetically-detoxified pertussis holotoxin |
US5358868A (en) * | 1987-11-24 | 1994-10-25 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
GB8727489D0 (en) * | 1987-11-24 | 1987-12-23 | Connaught Lab | Detoxification of pertussis toxin |
CA2009991A1 (en) * | 1989-02-15 | 1990-08-15 | Witold Cieplak | Pertussis toxin gene: cloning and expression of protective antigen |
US7232671B2 (en) * | 1989-02-15 | 2007-06-19 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Pertussis toxin gene: cloning and expression of protective antigen |
EP0396964B1 (en) * | 1989-04-28 | 1995-09-06 | SCLAVO S.p.A. | Pertussis toxin mutants, bordetella strains capable of producing such mutants and their use in the development of antipertussis vaccines |
US5786189A (en) * | 1989-11-29 | 1998-07-28 | Smithkline Beecham Biologicals (S.A.) | Vaccine |
GB9326174D0 (en) * | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
US20030072774A1 (en) * | 1994-06-10 | 2003-04-17 | Diane M. Gajewczyk | Proteinaceous adjuvants |
EP1234580A1 (en) * | 1995-05-04 | 2002-08-28 | Aventis Pasteur Limited | Acellular Pertussis Vaccines and Methods of Preparation Thereof |
WO1997043407A1 (en) * | 1996-05-10 | 1997-11-20 | Phylomed Corporation | Methods for oxidizing disulfide bonds using ozone |
FR2754543B1 (fr) * | 1996-10-11 | 1998-12-31 | Pasteur Institut | Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
GB0313916D0 (en) | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
CA2574953A1 (en) | 2004-07-26 | 2006-02-09 | Dow Global Technolgies Inc. | Process for improved protein expression by strain engineering |
CA2590906C (en) * | 2004-12-17 | 2017-01-03 | Nvi Nederlands Vaccininstituut | Deacylation of lps in gram negative bacteria |
US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
WO2008134461A2 (en) | 2007-04-27 | 2008-11-06 | Dow Global Technologies, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
ITMI20090946A1 (it) | 2009-05-28 | 2010-11-29 | Novartis Ag | Espressione di proteine ricombinanti |
MX343356B (es) | 2010-03-30 | 2016-11-03 | Pfenex Inc * | Toxinas proteicas recombinantes de alto nivel de expresion. |
US9169304B2 (en) | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
AU2013301312A1 (en) | 2012-08-06 | 2015-03-19 | Glaxosmithkline Biologicals S.A. | Method for eliciting in infants an immune response against RSV and B. pertussis |
MX362793B (es) | 2013-03-08 | 2019-02-13 | Janssen Vaccines & Prevention Bv | Vacuna acelular contra pertussis. |
BE1022008B1 (fr) | 2013-08-05 | 2016-02-03 | Glaxosmithkline Biologicals S.A. | Compositions immunogenes combinees |
CN109172818B (zh) * | 2018-08-02 | 2021-10-22 | 浙江康佰裕生物科技有限公司 | 一种蛋白牛痘疫苗及其效力检测方法 |
US20220047690A1 (en) * | 2018-10-15 | 2022-02-17 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Vaccine polypeptide compositions and methods |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4704362A (en) * | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
FR2590483B1 (fr) * | 1985-11-22 | 1988-12-09 | Pasteur Institut | Antigenes purifies ayant des proprietes vaccinantes contre b. pertussis, moyens notamment adns recombinants pour les produire et compositions de vaccins les contenant |
CA1340373C (en) * | 1986-01-28 | 1999-02-02 | Rino Rappuoli | Cloning and sequencing of the dna fragment which codes for the five subunits of the pertussis toxin, a hybrid plasmid containing the dna fragment and micro-organisms transformed by the hybrid plasmid and capable of expressing all or some of the subunits of the pertussis toxin |
EP0275689B1 (en) * | 1986-12-23 | 1992-09-02 | The Board Of Trustees Of The Leland Stanford Junior University | Modified pertussis exotoxin |
IT1223334B (it) * | 1987-11-02 | 1990-09-19 | Sclavo Spa | Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse |
GB8727489D0 (en) * | 1987-11-24 | 1987-12-23 | Connaught Lab | Detoxification of pertussis toxin |
IT1223529B (it) * | 1987-12-18 | 1990-09-19 | Sclavo Spa | Epitopo immunodominante protettivo contenuto nella subunita' s1 della tossina della pertosse |
-
1988
- 1988-08-26 JP JP63507460A patent/JP2918895B2/ja not_active Expired - Lifetime
- 1988-08-26 WO PCT/US1988/002983 patent/WO1989001976A1/en active IP Right Grant
- 1988-08-26 KR KR1019890700803A patent/KR0168039B1/ko not_active IP Right Cessation
- 1988-08-30 IL IL87608A patent/IL87608A0/xx not_active IP Right Cessation
- 1988-08-30 IL IL10312188A patent/IL103121A/en not_active IP Right Cessation
- 1988-09-01 DE DE3854213T patent/DE3854213T3/de not_active Expired - Lifetime
- 1988-09-01 ES ES88308124T patent/ES2076160T5/es not_active Expired - Lifetime
- 1988-09-01 EP EP88308124A patent/EP0306318B2/en not_active Expired - Lifetime
- 1988-09-01 EP EP94109317A patent/EP0629696A1/en not_active Withdrawn
- 1988-09-01 AT AT88308124T patent/ATE125568T1/de not_active IP Right Cessation
- 1988-09-02 IE IE266888A patent/IE69753B1/en not_active IP Right Cessation
- 1988-09-02 CA CA 576469 patent/CA1341560C/en not_active Expired - Fee Related
- 1988-09-05 CN CN88107056A patent/CN1033866C/zh not_active Expired - Lifetime
-
1989
- 1989-05-03 NO NO891842A patent/NO301844B1/no not_active IP Right Cessation
- 1989-05-03 FI FI892131A patent/FI101632B1/fi not_active IP Right Cessation
- 1989-05-03 DK DK198902162A patent/DK175821B1/da active
-
1992
- 1992-09-09 IL IL103121A patent/IL103121A0/xx unknown
-
1995
- 1995-06-06 US US08/468,679 patent/US5773600A/en not_active Expired - Lifetime
- 1995-09-21 GR GR950402614T patent/GR3017497T3/el unknown
-
1997
- 1997-06-09 NO NO19972642A patent/NO325016B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2076160T3 (es) | Analogos de las subunidades de la toxina de bordetella obtenidos a partir de adn recombinante. | |
ES2156110T3 (es) | Analogos de sub-unidades de toxina del colera derivados de adn recombinante. | |
ES2128320T3 (es) | Metodo criptocitotoxico binario de produccion de semilla hibrida. | |
AR020735A1 (es) | Un procedimiento para la obtencion de un polipeptido glucosilado a partir de celulas eucarioticas | |
CO5070674A1 (es) | Vacunas con un oligonucleotido cpg como adyuvante | |
CL2004001483A1 (es) | Procedimiento para producir una celula vegetal y un cultivo de estas, que son resistentes o tolerantes a un herbicida que inhibe a la glutamina sintetasa mediante la introduccion de un gen que codifica una acetil-transferasa; metodo para producir una | |
ES2119250T3 (es) | Composiciones y metodos para estimular el crecimiento y diferenciacion de megacariocitos. | |
FI881185A0 (fi) | Human mangan-superoxiddismutas (hmn-sod). | |
ATE181572T1 (de) | Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe | |
ES2094111T3 (es) | Proteinas con actividad de factor viii, procedimiento para su produccion que utilizan celulas modificadas por ingenieria genetica y composiciones farmaceuticas que las contienen. | |
IL196900A (en) | Autologous T cell vaccine compositions | |
AR027765A1 (es) | Expresion y purificacion de polipeptidos bioactivos autenticos a partir de plantas | |
ATE348876T1 (de) | Verfahren zur vermehrung von natürlichen killerzellen | |
FR2710074B1 (fr) | Gène GRB3-3, ses variants et leurs utilisations. | |
DE3850774D1 (de) | Rinder-interleukin-1-alpha. | |
RS75604A (en) | Microorganismus as carriers of nucleotide sequences coding for cell antigens used for the treatment of tumors | |
ATE246935T1 (de) | Zns neuroregenerative zusammensetzungen und deren verwendungen | |
ES2059472T3 (es) | Plantas con color de las flores modificado y procedimiento biotecnologico para su obtencion. | |
ATE414141T1 (de) | Verfahren zur kultivierung humaner chondrozyten | |
DE69837047D1 (de) | Verfahren zur herstellung verzweigtkettiger fettsäuren mittels genetisch modifizierter pflanzen | |
ES2062006T3 (es) | Un psti humano modificado. | |
ES2053766T3 (es) | Metodo para aumentar la expresion de un gen. | |
DE60033562D1 (de) | Künstliche promotoren zür protein expression in pflanzen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 306318 Country of ref document: ES |